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Abstract
Background: Leprosy is a chronic infectious disease caused by Mycobacterium leprae, an unculturable pathogen with an
exceptionally eroded genome. The high level of inactivation of gene function in M. leprae, including many genes in its
metabolic pathways, has led to a dependence on host energy production and nutritional products. We hypothesized that
host cellular powerhouse - the mitochondria - may affect host susceptibility to M. leprae and the onset of clinical leprosy,
and this may be reflected by mitochondrial DNA (mtDNA) background and mtDNA copy number.
Methods: We analyzed the mtDNA sequence variation of 534 leprosy patients and 850 matched controls from Yunnan
Province and classified each subject by haplogroup. mtDNA copy number, taken to be proportional to mtDNA content, was
measured in a subset of these subjects (296 patients and 231 controls) and 12 leprosy patients upon diagnosis.
Results: Comparison of matrilineal components of the case and control populations revealed no significant difference.
However, measurement of mtDNA copy number showed that lepromatous leprosy patients had a significantly higher
mtDNA content than controls (P=0.008). Past medical treatments had no effect on the alteration of mtDNA copy number.
Conclusions: Our results suggested that mtDNA content, but not haplogroup, affects leprosy and this influence is limited to
the clinical subtype of lepromatous leprosy.
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Introduction
Leprosy is a chronic infectious disease caused by an obligate
intracellular bacillus, Mycobacterium leprae. According to the WHO,
the total of newly registered leprosy patients in 2009 reached
211,903 and many regions in the world have not achieved the
leprosy elimination goal [1]. In the regions that had achieved the
elimination of leprosy, there are many new features and challenges
concerning case finding [2]. Evidently, leprosy remains and will
continue to be, a public health problem [1].
The genome of M. leprae has been well analyzed during the past
decade [3–4]. A comparison with M. tuberculosis, has shown that
more than half of the functional genes are inactivated or have
became pseudogenes in the M. leprae genome [3–5]. These
inactivated genes, many of which are predicted to be actively
involved in metabolic pathways, have resulted in M. leprae being an
intracellular parasite. The bacterium has a long half-life and has
yet to be cultured in vitro [4,6]. During the long evolutionary
erosion of its genome, M. leprae has developed a dependence on
host energy production and nutritional products and as a result the
parasitic life and adaptation might have shaped host genetic
susceptibility to leprosy [5,7,8].
Mitochondria play a key role in cellular energy supply, in vivo
generation of reactive oxygen species (ROS), regulation of
apoptosis and aging, and participation in innate immunity
[9,10]. The mitochondrion contains its own DNA, mitochondrial
DNA (mtDNA), which encodes 13 respiratory chain subunits, 2
ribosomal RNAs, and 22 tRNAs. Due to the specific character-
istics of mtDNA, e.g. maternal inheritance, absence of recombi-
nation and high mutation rate, each mtDNA lineage accumulated
mutations during evolution and a group of mtDNAs that share
certain mtDNA ancestral variants can be shown to belong to
distinguishable haplogroups [11,12]. Previous studies have shown
that the mtDNA haplogroup background affected genetic suscep-
tibility to many diseases, including maternally inherited diseases
[e.g. Leber’s hereditary optic neuropathy, LHON [13,14]],
metabolic diseases [e.g. diabetes [15,16]], infectious diseases [e.g.
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[18]]. Whether the mtDNA haplogroup background confers a
genetic susceptibility to leprosy has not been studied.
Each cell has hundreds to thousands of copies of mtDNA
molecules, and the alteration of mtDNA content has long been
recognized to be affected by the genetic background and factors in
the physiological environment, such as thyroid hormone level [19].
mtDNA content was said to be involved in tumorigenesis (e.g.
renal cell carcinoma [20] and non-Hodgkin lymphoma [21]) that
had a shift of energy production from oxidative phosphorylation to
glycolysis. Accumulating evidence showed that mtDNA copy
number control is very important for mitochondrial biogenesis and
normal cellular function [22]. Moreover, loss of mtDNA copy
number was also reported as the cause of mtDNA depletion
syndrome [23].
In this study, we hypothesized that erosion of the M. leprae
genome during its evolution has led to a strong dependence on
host energy production and nutritional products, and would confer
a genetic susceptibility to leprosy. By dissecting the matrilineal
genetic structure of case and control populations and analyzing the
mtDNA content in mitochondria, which act as host cellular
powerhouse and are actively involved in critical pathways for
innate immunity [9,10], we may have a method of testing this
hypothesis. Our comparison of mtDNA haplogroup distribution
frequency and mtDNA copy number in leprosy patients and
healthy controls showed that mtDNA copy number, but not
haplogroup, was associated with lepromatous leprosy.
Materials and Methods
Ethics Statement
Written informed consents conforming to the tenets of the
Declaration of Helsinki were obtained from each participant prior
to the study. The institutional review board of the Kunming
Institute of Zoology approved this study.
Subjects
The study included 534 treated leprosy patients (390 males and
144 females, age from 17 to 98 years) with detailed clinical data
and 850 matched normal controls (467 males and 383 females, age
from 3 to 91 years) without any history of leprosy, HIV infection
and tuberculosis from nine regions of Yuxi Prefecture, Yunnan
Province in Southwest China (Figure S1). The Yuxi Prefecture of
Yunnan Province (north latitude 23u 199–24u 539, longitude 101u
169–103u 99) is historically an endemic region of leprosy [2] and
contains eight counties (Jiangchuan, Chengjiang, Tonghai, Huan-
ing, E’shan, Yimen, Xinping, and Yuanjiang) and one district
(Hongta). In our recent study, we have reported the leprosy
diagnosis, control, and treatment results in this region from 1952
to 2008 [2].
Patients were diagnosed on the basis of clinical presentation and
histopathological features, as well as bacteriological index (if
available), following the approach described in Li et al. [2]. The
clinical data for those patients were described in our recent study
[2], and the onset age of the patients ranged from 2 to 67 years.
283 of the patients had been diagnosed with multibacillary leprosy
(MB, including lepromatous [LL], borderline-lepromatous [BL]
and mid-borderline leprosy [BB] based on the Ridley–Jopling
classification [24]) and 249 with paucibacillary leprosy (PB,
including tuberculoid [TT] and borderline-tuberculoid [BT]
leprosy on the basis of the Ridley–Jopling classification) according
to the latest WHO case definition [25]. Two samples had an
unclear classification of leprosy subtype due to lack of detailed
information.
392 patients had been treated by Dapsone (DDS) monotherapy
and/or Rifampicin (RFP), of which 34 patients experienced
relapse. 142 patients had been treated with the WHO multi-drug
therapy (MDT). All the relapsed patients were subsequently
treated by MDT. Disability levels were graded according to the
revised WHO grading system [26]. Samples from 12 newly
diagnosed patients prior to any treatment were collected from
Wenshan, Yunnan (7 males and 5 females, age from 13 to 80 year)
(Figure S1).
Sequencing mtDNA Control Region and Haplogroup
Classification
Genomic DNA was extracted from peripheral blood by using
the AxyPrep
TM Blood Genomic DNA Miniprep Kit (Axygen,
USA). The mtDNA control region sequence of each patient and
control was amplified by using primer pair (L15594, 59-
CGCCTACACAATTCTCCGATC-39/H901, 59-ACTTGGGT-
TAATCGTGTGACC-39 or H650, 59-GAAAGGCTAGGAC-
CAAACCTA-39) [27]. PCR products were purified and
sequenced following the same method described in our recent
study [27,28]. Sequence variation was scored relative to the
revised Cambridge reference sequence (rCRS) [29]. Each
mtDNA was classified into the smallest named haplogroup
according to the available mtDNA phylogeny for East Asian
[11,30] by employing the same strategy in our previous studies
[13,28]. For samples which could not be unambiguously
classified based on the mtDNA control region sequence
variation, PCR- restriction fragment length polymorphism
(RFLP) analysis for haplogroup-specific coding region variant(s)
was performed to justify the assignment [13,28].
Measurement of mtDNA Copy Number
Relative mtDNA copy number was measured by the fluores-
cence-based quantitative real-time PCR as previously described in
our recent study [31]. In brief, primer pair L394, 59-CAC-
CAGCCTAACCAGATTTC-39/H475, 59-GGGTTGTATT-
GATGAGATTAGT-39 was used for measuring the mtDNA
and the amplification of the single-copy nuclear b-globin gene
(HBB502f, 59-CTATGGGACGCTTGATGT-39/HBB614r, 59-
GCAATCATTCGTCTGTTT-39) was used for normalization.
The ratio of mtDNA to nuclear DNA, the relative mtDNA copy
number, reflects the relative mtDNA content per cell. The
amplification assays were performed with SYBRH Premix Ex
Taq
TM II kit (TaKaRa Biotechnology Co. Ltd. [Dalian, China])
according the manufacturer’s manual on the MyiQ2 system
(BioRad Laboratories, Hercules, CA, USA).
Statistical Analysis
Pearson’s chi-square test with a one degree of freedom was used
to assess the significance of differences observed for haplogroup
distribution frequencies between leprosy patients and controls.
The Fisher’s exact test (two tailed) was applied to those cases with
cell counts below five. Principal component analysis (PCA) was
performed based on the mtDNA haplogroup distribution frequen-
cy to show the overall clustering pattern of leprosy and control
populations from Yuxi with reported Han Chinese populations
across China (Zhang et al. [28] and references therein) by using
POPSTR software (http://harpending.humanevo.utah.edu/
popstr/).
The mtDNA copy number was compared between the case
group and the control group by using Student’s t test. Difference of
mtDNA copy number among three or more groups was evaluated
by one-way analysis of variance (ANOVA). Dunnett’s test was
mtDNA and Leprosy
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groups. SPSS 15.0 was used for all statistical analysis. A P value
,0.05 was considered statistically significant.
Results
Lack of Association of mtDNA Haplogroup with Leprosy
The patient and control populations from nine regions of the
Yuxi Prefecture had various sample size, ranging from 16 to 164
individuals (Figure S1). We therefore pooled all the cases and
controls from different regions of Yuxi as one case population and
one control population for analysis, respectively, and excluded the
12 samples from Wenshan. All 1384 subjects (534 patients and 850
controls) could be classified into known haplogroups in East and
South Asians [11,30] based on mtDNA variation, with a few
lineages with unassigned M*, N* and R* status (Table S1). There
was no significant difference in mtDNA haplogroup frequency
between the patients and controls (Table 1). When the leprosy
patients were classified into two groups (MB group [N=288) and
PB group [N=256]) according to their clinical features, no
haplogroup was found to be associated with leprosy subtype
relative to controls (Table 1). To further demonstrate the similarity
of matrilineal genetic structures of leprosy patient and control
populations from Yuxi, we constructed a PC map for these two
populations, together with reported Han Chinese populations
across China (Zhang et al. [28] and references therein). The
leprosy patient and control populations were clustered together,
suggesting no essential difference between them (Figure 1). This
result further indicated the absence of any association of mtDNA
haplogroup with leprosy.
Increase of mtDNA Copy Number in Lepromatous
Leprosy Patients
To test whether alterations of mtDNA copy number affected
leprosy, we measured the mtDNA copy number in samples from
296 randomly selected patients (224 males and 72 females, age
from 35 to 98 year) and 231 matched controls (142 males and 89
females, age from 13 to 85 year) from Yuxi. Twelve newly
diagnosed patients prior to treatment from Wenshan were also
analyzed to determine any potential effect of drug treatment on
mtDNA content (Table 2). Twenty-two samples were measured
twice to assess the reproducibility of our technique and we
observed similar results in the two replicates.
As shown in Figure 2, there was a slight increase of mtDNA
copy number in all leprosy patients (Mean 6 SD, 63.76637.45)
compared to control subjects (59.46619.29) (P=0.086). When we
grouped the leprosy patients according to their case definition (MB
versus PB), we found that the observed higher level of mtDNA
copy number in leprosy patients was mainly contributed by MB
patients (versus control, P=0.099), although there was no
significant difference of mtDNA copy number between MB group
(66.21637.62; n=168) and PB group (60.90637.40; n=138)
(P=0.219; the 2 cases from Yuxi with an unclear leprosy type
were excluded). Further assignment of patients according to the
Ridley–Jopling classification system [24] showed that patients with
lepromatous leprosy had a significantly higher level of mtDNA
copy number compared to the control sample (P=0.008), whereas
the other types of leprosy showed no significant difference with the
controls (Figure 2). We observed a significantly elevated level of
mtDNA copy number in the cured patients from Yuxi with
advanced age (.61 year) compared to patients with age younger
than 61 (P=0.015; Table 2). However, there was no essential
change of mtDNA copy number with age in the controls and this
observation was consistent with previous reports [20,32]. The
increased level of mtDNA copy number in Yuxi cases with
advanced age was not simply caused by a greater number of LL
cases in this group (32% of LL cases had an age ,61 years and
68% of LL patients had an age .61 years), as we still observed a
higher level of mtDNA copy number in cured patients with
advanced age than in patients with young age after we excluded all
LL patients (P=0.049). Because there was no statistical difference
in age between the MB and PB groups and among the five patient
groups according to the Ridley–Jopling classification system, the
increased mtDNA content in LL patients was unlikely to be caused
by age difference. A comparison of mtDNA copy number in
samples with different haplogroup status showed that haplogroup
background did not affect mtDNA content (Table S2). Taken
together, the above observed difference should be attributed to the
lepromatous leprosy subtype.
To test whether long-term treatment to cure leprosy had an
effect on mtDNA copy number, we measured the level of mtDNA
copy number in patients who had received the different drug
treatments of DDS and/or RFP (63.73636.64) and MDT
(65.51640.53), and found that both groups showed similar values.
Moreover, the level of mtDNA copy number in the 12 leprosy
patients prior to any medical treatment was within the range of
that observed in the cured patients and control subjects from Yuxi,
suggesting no effect of past treatment on alteration of mtDNA
copy number (Figure 2).
We followed the WHO disability grading [26], which scored
different level of severity of impairment on limbs (hands and feet)
and eyes, to group all patients into three groups. Intriguingly, we
found that patients with no anesthesia, no visible deformity and
damage, and no visual loss and other eye problem (Grade 0) had a
higher level of mtDNA copy number (73.33633.98) relative to the
control (P,0.001). There was a decreasing tendency for the
relative level of mtDNA copy number in all patients with
increasing disability grading (Grade I, 66.53643.48; Grade II,
55.73636.69) (Figure 3). However, this tendency was not
correlated with disability grade observed in LL cases (Grade 0,
83.32632.1; Grade I, 64.0615.7; and Grade II, 72.4642.7).
Discussion
In recent years, many human disorders have been reported to
be associated with mtDNA haplogroup [13–18,28] and/or
alteration of mtDNA content [20,21,33]. Due to the intrinsic
characteristics of the eroded genome of M. leprae, we would expect
that host mtDNA background and content would confer genetic
susceptibility to leprosy. Moreover, accumulating evidence has
suggested that mitochondria play an essential role in the innate
immunity response to microbial infection [9,10,34], and this
innate immune response may play a crucial role in determining
whether mycobacterial infection progresses to the clinical disease
of leprosy [35,36]. Analyses of mtDNA haplogroup distributions in
case-control studies have reported positive associations of mtDNA
variants/haplogroups with infectious complications and sepsis
[17,18,37–39], although there are negative reports, e.g. lack of
association with mtDNA haplogroups and meningococcal disease
[40].
In this study, we analyzed mtDNA haplogroup distribution and
mtDNA copy number variation in a large cohort of leprosy
patients and matched controls from Southwest China, to test
whether mtDNA variation confers a genetic susceptibility to
leprosy. We found that mtDNA content, but not mtDNA
haplogroup, was associated with lepromatous leprosy. To our
knowledge, this is the first report to link mtDNA variation with
genetic susceptibility to leprosy.
mtDNA and Leprosy
PLoS ONE | www.plosone.org 3 June 2012 | Volume 7 | Issue 6 | e38848A previous study reported that sepsis was associated with
reduction of mtDNA content in circulating monocytes and
lymphocytes, which influence the innate immune response to
infections [33], and longitudinal increases of mtDNA copy number
in blood cells was associated with survival in critically ill patients
[41].TheLLtypeofleprosyisknowntoharboragreaternumberof
bacilli and be predisposed to low cell mediated immunity [42].
Whetherthe highermtDNAcopy numberinLLpatientsnegatively
impacts on the immune response to M. leprae infection remains
elusive.WespeculatedthatthehigherlevelofmtDNAcontentinLL
patients might be associated with the development of lepromatous
leprosy, which was accompanied by the secretion of cytokines and
possiblyincreasedoxidativestress.Indeed,apreviousstudybyLeeet
al.[43]haveshownthatcellularmtDNAcontentandmitochondrial
mass would increase in response to oxidative stress. However, we
must confess that this speculation could not explain the fact that we
failed to observe a graded difference in mtDNA copy number from
polar tuberculoid to lepromatous leprosy, as expected from the
increasing bacterial load. Because there was no statistical difference
intheagesoftheLLgroupandtheotherpatientgroups,theelevated
level of mtDNA copy number in LL patients could not be simply
explained by the potential age difference. Moreover, we still
observed a higher level of mtDNA copy number in patients with
advanced age after we excluded all LL cases. The disability in
leprosypatientswasdirectlyrelatedtohostimmunologicalreactions
and early access to treatment [42]. We observed a decreasing
tendency for the relative level of mtDNA copy number in patients
with increasing disability grading. The exact reason for this
difference awaits further study.
Some antibiotics could cause decreased cell growth, reduced
mitochondrial mass, impaired respiratory complex activities and
mitochondrial protein synthesis, but these inhibition effects could
be reversed after stopping the antibiotic [44]. The majority of our
patients who received treatment were cured more than a decade
Table 1. Haplogroup frequencies and Pearson’s chi-square test in leprosy patients and controls from Yuxi, Yunnan Province in
Southwest China.
Haplogroup
# Controls Leprosy patients MB patients PB patients
No. No. P-value* OR 95% CI No. P-value* OR 95% CI No. P-value* OR 95% CI
C 45 19 0.134 1.515 0.876–2.620 8 0.089 1.922 0.895–4.127 10 0.416 1.336 0.663–2.691
Z 24 20 0.341 0.747 0.408–1.365 10 0.544 0.793 0.375–1.680 10 0.339 0.694 0.327–1.473
CZ 72 39 0.436 1.175 0.783–1.762 18 0.256 1.362 0.798–2.326 20 0.839 1.055 0.629–1.769
M7b 39 18 0.267 1.379 0.780–2.436 12 0.807 1.086 0.560–2.104 6 0.127 1.948 0.815–4.655
M7c 8 8 0.345 0.625 0.233–1.675 4 0.508 0.663 0.198–2.218 4 0.485 0.582 0.174–1.949
M7 47 27 0.703 1.099 0.676–1.787 17 0.763 0.916 0.517–1.622 10 0.350 1.393 0.693–2.799
M8a 17 6 0.214 1.796 0.704–4.584 2 0.185 2.867 0.658–12.488 4 1.000 1.250 0.417–3.750
M9a 24 12 0.512 1.264 0.627–2.549 5 0.330 1.615 0.611–4.275 7 0.992 1.004 0.428–2.360
M11 5 4 0.740 0.784 0.210–2.933 1 1.000 1.669 0.194–14.344 3 0.391 0.485 0.115–2.045
M12 6 7 0.256 0.535 0.179–1.601 2 1.000 0.999 0.200–4.977 5 0.069 0.347 0.105–1.146
M25 5 4 0.740 0.784 0.210–2.933 0 – – – 4 0.124 0.362 0.097–1.360
M71 9 4 0.776 1.418 0.434–4.628 2 0.741 1.504 0.323–7.001 2 1.000 1.322 0.284–6.157
M74 5 4 0.740 0.784 0.210–2.933 2 1.000 0.831 0.160–4.309 2 0.660 0.731 0.141–3.790
D4 100 58 0.607 1.094 0.776–1.542 37 0.558 0.886 0.592–1.327 21 0.140 1.448 0.884–2.371
D5 28 16 0.758 1.103 0.591–2.058 8 0.698 1.171 0.527–2.599 7 0.703 1.178 0.508–2.729
D 128 75 0.604 1.085 0.797–1.476 45 0.733 0.938 0.648–1.357 29 0.183 1.339 0.870–2.059
G 53 38 0.520 0.868 0.564–1.336 21 0.485 0.830 0.491–1.402 17 0.737 0.908 0.516–1.598
A 80 44 0.457 1.157 0.787–1.700 23 0.515 1.174 0.723–1.907 21 0.638 1.128 0.682–1.865
N9a 23 13 0.757 1.115 0.560–2.220 8 0.914 0.956 0.423–2.162 5 0.539 1.357 0.511–3.608
B4 100 77 0.150 0.791 0.575–1.089 44 0.098 0.724 0.494–1.063 33 0.527 0.873 0.573–1.330
B5 43 25 0.752 1.085 0.655–1.798 10 0.293 1.455 0.721–2.934 15 0.549 0.831 0.454–1.523
B 148 108 0.604 1.085 0.797–1.476 57 0.302 0.836 0.595–1.175 51 0.257 0.814 0.571–1.162
F1 123 82 0.652 0.933 0.689–1.263 48 0.311 0.828 0.575–1.193 34 0.746 1.070 0.711–1.611
F2 14 14 0.210 0.622 0.294–1.315 6 0.601 0.773 0.294–2.031 8 0.121 0.504 0.209–1.217
F3 8 4 0.776 1.259 0.377–4.201 4 0.508 0.663 0.198–2.218 0 – – –
F 154 111 0.219 0.843 0.642–1.107 63 0.125 0.773 0.555–1.075 48 0.658 0.922 0.643–1.322
R9b 14 4 0.222 2.219 0.727–6.777 0 – – – 4 1.000 1.026 0.335–3.145
R9 172 117 0.456 0.904 0.694–1.178 64 0.393 0.868 0.627–1.201 53 0.718 0.938 0.663–1.327
Others 56 32 0.658 1.106 0.707–1.733 16 0.577 1.177 0.664–2.087 16 0.927 1.027 0.578–1.824
*P-value was calculated by Pearson’s chi-square test; Fisher’s exact test was used when haplogroup occurred in less than five individuals.
#Haplogroup occurred in less than four individuals in the entire case or control population and those unassigned M*, N* and R* mtDNAs were pooled together. We
presented these nested haplogroups according to their phylogenetic positions, e.g. D contains D4, D5, D6 and D*.
doi:10.1371/journal.pone.0038848.t001
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RFP had similar level of mtDNA content compared with those
who received MDT, suggesting that mtDNA content might not be
affected by different drugs. Moreover, the mtDNA content in
leprosy patients prior to any medical treatment was within the
range that was observed in cured patients and control subjects
(Figure 2), albeit the overall level of mtDNA content was lower in
these untreated patients (Table 2) and the sample size was very
small. All these observations seemed to suggest that past medical
treatments might not have an effect on mtDNA content. Because
we did not collect patients who are undergoing therapy, we do not
know whether there is a change of mtDNA content upon drug
treatment. In addition, it would be worthwhile to compare
mtDNA copy number at the time of relapse and the time of last
treatment in the same patients, to test whether there are alterations
of mtDNA copy number.
In summary, we found no mtDNA haplogroup that was
associated with leprosy but observed an increased mtDNA copy
Figure 1. Principal component analysis of leprosy patient and control populations from Yuxi and reported Han Chinese
populations across China. (a) PC map of Han regional populations based on mtDNA haplogroup frequencies (.1%). The patient (YuxiCase) and
control (YuxiControl) populations from Yuxi were marked by triangles, whereas the reported Han Chinese populations (Zhang et al. [28] and
references therein) were marked by open circles. (b) Plot of the haplogroup contribution to the first and second PCs.
doi:10.1371/journal.pone.0038848.g001
Table 2. Demographic information and mtDNA content in the case and control groups.
Variable Yuxi cases (N=296)
a Wenshan cases (N=12) Controls (N=231)
No. (%) mtDNA content (mean ± SD) No. (%) mtDNA content (mean ± SD) No. (%) mtDNA content (mean ± SD)
Sex
Male 224 (75.7) 64.18638.30 7 (58.3) 44.41612.38 142 (61.5) 58.93619.69
Female 72 (24.3) 64.94636.91 5 (41.7) 55.28625.52 89 (38.5) 60.31618.72
P-value
{ 0.882 0.416 0.597
Age, year
, mean age
* 139 (47.0) 58.73633.57 7 (58.3) 42.9069.14 122 (52.8) 59.14619.87
. mean age 157 (53.0) 69.36640.83 5 (41.7) 57.39626.24 109 (47.2) 59.83618.71
P-value
{ 0.015 0.293 0.786
WHO classification
#
MB 163 (55.4) 66.97637.88 5 (41.7) 41.29612.89 – –
PB 131 (44.6) 61.10637.98 7 (58.3) 54.41621.22 – –
P-value
{ 0.187 0.250 –
Treatment
MDT 102 (34.6) 65.51640.53 – – – –
DDS/RFP 193 (65.4) 63.73636.64 – – – –
P-value
{ 0.703 – –
*The mean age varied in each group of subjects (Mean 6 SD, Yuxi case: 61.1612.3; Wenshan case: 34.5621.3; Control: 39.9616.8).
{Student’s unpaired t test (two-sided) was used to quantify the differences.
#Two cases from Yuxi had unclear leprosy types were excluded. All leprosy patients from Wenshan received no treatment prior to blood sample collection.
doi:10.1371/journal.pone.0038848.t002
mtDNA and Leprosy
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observation could be compatible with the notion of a higher
cellular energy supply facilitating the survival and persistence of M.
leprae in vivo. On this point, our current result is compatible with
our hypothesis that host cellular powerhouse - the mitochondria -
may affect the susceptibility to M. leprae and the development of
clinical leprosy. Functional characterization of mitochondria in
patients with leprosy should be performed to independently
validate our findings.
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Figure 2. Comparison of the relative mtDNA copy number in leprosy patients (n=308) and matched healthy controls (n=231).
Student’s unpaired t test was used to quantify the statistical difference between the leprosy patient and control groups. Leprosy patients were either
grouped into multibacillary leprosy (MB) and paucibacillary leprosy (PB) according to the latest WHO case definition [25] or into lepromatous (LL),
borderline-lepromatous(BL), mid-borderlineleprosy (BB),borderline-tuberculoid(BT),andtuberculoid(TT)basedonthe Ridley–Joplingclassification [24].
One-way analysis of variance (ANOVA) of the mean values was used to analyze the difference of mtDNA copy number among groups (for comparison
among MB, PB and control groups, P=0.089; for comparison among LL, BL, BB, BT, TT and control groups, P=0.003); the Dunnett’s test was further used
for multiple comparisons between any of the two groups. The 12 untreated leprosy samples from Wenshan were marked with stars in MB, PB and case
groups, and the two patients with unclear classification were excluded from the analysis when we grouped the patients into MB and PB groups.
doi:10.1371/journal.pone.0038848.g002
Figure 3. Relative levels of mtDNA copy number in leprosy
patients with different grades of disability. One-way analysis of
variance (ANOVA) of the mean values was used to analyze the
difference of mtDNA copy number among groups (with a P value
,0.001) and the Dunnett’s test was used for multiple comparisons
between any of the two groups.
doi:10.1371/journal.pone.0038848.g003
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